Short Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Increases By 8.8%

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) saw a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 8,520,000 shares, an increase of 8.8% from the November 15th total of 7,830,000 shares. Based on an average daily volume of 894,400 shares, the short-interest ratio is presently 9.5 days.

4D Molecular Therapeutics Stock Down 2.5 %

FDMT traded down $0.16 during trading on Tuesday, hitting $6.32. 762,557 shares of the stock were exchanged, compared to its average volume of 885,128. 4D Molecular Therapeutics has a 1-year low of $6.28 and a 1-year high of $36.25. The stock has a fifty day moving average price of $7.97 and a two-hundred day moving average price of $14.22. The firm has a market capitalization of $292.16 million, a P/E ratio of -2.22 and a beta of 2.74.

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds have recently modified their holdings of FDMT. nVerses Capital LLC purchased a new stake in 4D Molecular Therapeutics during the third quarter worth about $40,000. Values First Advisors Inc. purchased a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth approximately $57,000. China Universal Asset Management Co. Ltd. increased its stake in 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company's stock valued at $108,000 after purchasing an additional 3,922 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in 4D Molecular Therapeutics during the third quarter worth $108,000. Finally, Quest Partners LLC boosted its position in 4D Molecular Therapeutics by 17,409.1% during the second quarter. Quest Partners LLC now owns 5,778 shares of the company's stock worth $121,000 after purchasing an additional 5,745 shares in the last quarter. 99.27% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

FDMT has been the topic of several recent research reports. Cantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, September 23rd. Leerink Partners restated an "outperform" rating and issued a $36.00 target price (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Morgan Stanley initiated coverage on 4D Molecular Therapeutics in a research report on Thursday, November 21st. They issued an "underweight" rating and a $8.00 price objective on the stock. Chardan Capital reaffirmed a "buy" rating and set a $39.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Finally, Royal Bank of Canada cut their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating for the company in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $42.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.